The Significant Rise In Biotherapeutics Manufacturing Is Anticipated To Open Up New Avenue For Protein A Resin Market.
The Protein A Resin Market is estimated to be valued at US$ 656.9 Mn in 2023 and is expected to exhibit a CAGR of 8.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Protein A resin is used for affinity chromatography to capture antibodies and other immunoglobulins from protein samples. It helps in the purification and isolation of monoclonal antibodies during the manufacturing of biologics drugs. Major application areas include monoclonal antibody purification, IgG purification, recombinant protein purification, and vaccine purification.
Market Dynamics:
Increasing Biologics Drug Approvals- Over the past decade, biologics drug approvals have witnessed significant growth. Increasing adoption and success of biologics in the treatment of various chronic and life-threatening diseases is driving the demand for protein A resins for purification during manufacturing.
Rising Research and Development Expenditure- Growing expenditure on research and development by biopharmaceutical companies to develop novel biologics is fueling the development and commercialization of advanced protein A resins. Various players are focusing on developing resins with enhanced binding capacity and selectivity.
Segment Analysis
The protein A resin market can be segmented into natural protein A and recombinant protein A. Recombinant protein A is the dominating sub-segment currently accounting for over 70% share due to advantages over natural protein A including better stability and reduced contamination risk. Recombinant protein A resins are produced by genetically engineered bacteria which express gene sequences coding for protein A, thereby providing highly purified protein A without contamination.
PEST Analysis
Political: The market is favorably impacted by support for research innovation in life sciences across major countries. However, stringent regulations can increase compliance costs for players.
Economic: Growing biopharmaceutical industry, rising healthcare spending, and increasing R&D investments are fueling market growth. However, high costs of protein A resins remain a challenge.
Social: Increasing prevalence of chronic diseases is driving demand for biologics and monoclonal antibodies production which utilizes protein A resins.
Technological: Advancements in chromatography techniques, resins, and purification systems have improved productivity and efficiency. Continuous development of specialty ligands enhances selectivity and binding capacities.
Key Takeaways
The Global Protein A Resin Market Growth is expected to witness high growth, exhibiting CAGR of 8.5% over the forecast period, due to increasing demand for monoclonal antibodies and recombinant proteins.
The North America region currently dominates the protein A resin market accounting for over 45% share due to presence of major players and growing biopharmaceutical R&D expenditure. Asia Pacific is expected to witness fastest growth owing to increasing pharmaceutical production and expanding biotech industry in China and India.
Key players operating in the protein A resin market are GE Healthcare, Thermo Fisher Scientific, Repligen, Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd. Major players are focusing on new product innovations, capacity expansions and mergers & acquisitions to strengthen their market position.